Aptevo Therapeutics (NASDAQ:APVO) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01, Fidelity Earnings reports. Aptevo Therapeutics had a negative return on equity of 148.97% and a negative net margin of 195.98%. The firm had revenue of $9.01 million for the quarter, compared to the consensus estimate of $8.05 million.
Shares of APVO stock traded up $0.04 during trading hours on Friday, reaching $0.65. The company had a trading volume of 727,500 shares, compared to its average volume of 519,858. The company has a 50 day moving average of $0.61 and a 200 day moving average of $0.75. Aptevo Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.65. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.63 and a quick ratio of 2.21. The firm has a market cap of $29.33 million, a price-to-earnings ratio of -0.27 and a beta of 2.44.
A number of research analysts have recently weighed in on the company. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research downgraded Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 16th. Finally, Piper Jaffray Companies cut their price target on Aptevo Therapeutics from $4.50 to $3.00 in a research note on Friday, October 4th.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Featured Article: Ex-Dividend
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.